STDs Reach Record Highs

 A report from the CDC shows sexually transmitted diseases (STDs) at a record high, with staggering health consequences for millions of Americans. 

“At a time when Congress is debating repeal of the Affordable Care Act, cuts to state STD funding, and whether young people should be provided comprehensive sex education, we can ill afford to roll back the clock,” says David C. Harvey, executive director of the National Coalition of STD Directors, in a news release. “We need our leaders to declare war on STDs and to do what it takes to bring down these rates and increase federal funding.”

The CDC report shows syphilis rates increased by 17.6 percent over 2015 numbers, including a 35 percent increase in women. Syphilis rates are at levels not seen since 1992 and disproportionately impact Black and Latino gay men. Babies born with syphilis increased by 27.5 percent, with seven new states reporting cases over 2015. Chlamydia increased by 4.7 percent and gonorrhea rates were up 18.5 percent. The US has almost 20 million STDs a year, with a cost to the health care system of $16 billion.

“STDs can be prevented if we have the will,” Mr. Harvey adds. “On behalf of state STD prevention and care programs, we call upon the Trump Administration and Congress to support a $40 million increase to STD funding over FY 2017 funding levels to provide a much needed jump-start for state and local health departments and clinics to fight the rise in STDs.”

STDs can have dire health consequences, especially for young women and newborn babies, two populations who are increasingly at risk, according to the CDC report. The long-term health consequences posed by STDs are serious and often irreversible, especially if not diagnosed and treated early. Young people ages 15-24 and gay and bisexual men are at highest risk for STDs and can drive new HIV infections. Young people face unique barriers to services, including stigma, confidentiality concerns, and limited access to expert STD providers. Left untreated, women can experience infertility, PID, ectopic pregnancies and chronic pelvic pain from STDs. Drug-resistant gonorrhea is a major public health threat, since increased resistance to the antibiotics used to treat the condition has been reported around the globe.

RXI Completes Enrollment of Phase 2 Study of Samcyprone for Cutaneous Warts

RXi Pharmaceuticals Corporation completed enrollment in its Phase 2 clinical trial, RXI-SCP-1502, with Samcyprone for the clearance of cutaneous warts.

Samcyprone is a proprietary topical formulation of the small molecule diphenylcyclopropenone (DPCP). This topical immunomodulator works by initiating a T-cell response. DPCP has been used for several decades by physicians and is supported in publications for its use as an immunomodulator for the treatment of warts, alopecia areata and cutaneous metastases of malignant melanoma.

It has never been reviewed or approved by a regulatory authority as a drug; however, DPCP is a new chemical entity under a US investigational new drug application (IND). The company’s proprietary topical formulation of DPCP, Samcyprone, is expected to achieve market exclusivity post approval. In March 2015, the company was granted orphan drug designation for Samcyprone by the FDA for the treatment of malignant melanoma stage IIb to IV.

RXi Pharmaceuticals Corporation completed an exclusive global license to Samcyprone from Hapten Pharmaceuticals, LLC. After the transfer of the IND to RXi, the dompany completed a process to optimize the topical formulation followed by the initiation of its Phase 2 study, RXI-SCP-1502.


Practical Approaches to Nail Disorders

Dana Stern, MD and Josh Zeichner, MD to discuss the recent advances in understanding the pathophysiology of brittle nails and the most effective treatments available. Dr. Stern offers practical tips to share with patients from products to avoid to what kind of protective gloves they should wear to the best type of nail file to use.

This study is a multi-center, multi-dose trial conducted in subjects with at least one cutaneous, plantar or periungual wart present for at least four weeks. In this Phase 2 trial, subjects are first treated with a sensitization dose on the inner arm and one or more preselected wart lesion(s). Once the sensitization response is confirmed, subjects continue with weekly treatments for 10 weeks. Wart clearance will be evaluated based on Investigator’s Global Assessment Score (IGAS) and wart measurements over time during the treatment period.

What’s the Role of Demodex Mite Infestation in Rosacea?

A recent evidence-based meta-analysis was conducted to assess the prevalence and degrees of Demodex mite infestation in patients with rosacea.

A systematic literature review and meta-analysis were conducted, and odds ratios for prevalence of infestation and standardized mean difference (SMD) for Demodex density in patients with rosacea were pooled. Subgroup analysis for type of rosacea, control group, and sampling and examination methods were also performed.

The analysis looked at 23 case-control studies including 1513 patients with rosacea. Compared with the control patients, patients with rosacea were more likely to be infested by Demodex mites and had significantly higher Demodex density. Both erythematotelangiectatic rosacea and papulopustular rosacea had significantly higher Demodex density compared to healthy control patients. The analysis led the study authors to conclude that “Demodex mites may play a role in both erythematotelangiectatic rosacea and papulopustular rosacea.”

However, the analysis was limited in that interstudy variability was high, and a causal relationship could not be established by case-control studies.

—JAAD; 77(3): 441–447.e6